PURPOSE: This study investigated the effect of the herbal medicine baicalin on bupropion hydroxylation, a probe reaction for CYP2B6 activity related to different CYP2B6 genotype groups. METHOD: Seventeen healthy male volunteers (6 CYP2B6*1/*1, 6 CYP2B6*1/*6, and 5 CYP2B6*6/*6) received orally administered bupropion alone and during daily treatment with baicalin. Blood samples were taken up to 72 h after each bupropion dose, and pharmacokinetics profiles were determined on days 1 and 25 for bupropion and hydroxybupropion. RESULT: Baicalin administration increased hydroxybupropion maximum plasma concentration (C(max)) by 73% [90% confidence interval (CI), 44-108%; P < 0.01] and the area under the concentration time curve extrapolated to infinity (AUC(0-infinity)) of hydroxybupropion by 87% (90% CI, 48-137%; P < 0.01), with no change in the elimination half-life of hydroxybupropion. Baicalin increased the AUC(0-infinity) ratio of hydroxybupropion to bupropion by 63% (90% CI, 38-92%; P < 0.01). CONCLUSION: Baicalin significantly induced CYP2B6-catalyzed bupropion hydroxylation, and the effects of baicalin on other CYP2B6 substrate drugs deserve further investigation.
PURPOSE: This study investigated the effect of the herbal medicinebaicalin on bupropion hydroxylation, a probe reaction for CYP2B6 activity related to different CYP2B6 genotype groups. METHOD: Seventeen healthy male volunteers (6 CYP2B6*1/*1, 6 CYP2B6*1/*6, and 5 CYP2B6*6/*6) received orally administered bupropion alone and during daily treatment with baicalin. Blood samples were taken up to 72 h after each bupropion dose, and pharmacokinetics profiles were determined on days 1 and 25 for bupropion and hydroxybupropion. RESULT: Baicalin administration increased hydroxybupropion maximum plasma concentration (C(max)) by 73% [90% confidence interval (CI), 44-108%; P < 0.01] and the area under the concentration time curve extrapolated to infinity (AUC(0-infinity)) of hydroxybupropion by 87% (90% CI, 48-137%; P < 0.01), with no change in the elimination half-life of hydroxybupropion. Baicalin increased the AUC(0-infinity) ratio of hydroxybupropion to bupropion by 63% (90% CI, 38-92%; P < 0.01). CONCLUSION:Baicalin significantly induced CYP2B6-catalyzed bupropion hydroxylation, and the effects of baicalin on other CYP2B6 substrate drugs deserve further investigation.
Authors: S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton Journal: J Pharmacol Exp Ther Date: 1998-09 Impact factor: 4.030
Authors: Virginia Borges; Eric Yang; John Dunn; Jack Henion Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-05-25 Impact factor: 3.205
Authors: M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin Journal: Mol Pharmacol Date: 2004-09 Impact factor: 4.436
Authors: Melanie S Joy; Reginald F Frye; Kristi Stubbert; Kim R Brouwer; Ronald J Falk; Evan D Kharasch Journal: J Clin Pharmacol Date: 2010-01-26 Impact factor: 3.126
Authors: Zeruesenay Desta; Ahmed El-Boraie; Li Gong; Andrew A Somogyi; Volker M Lauschke; Collet Dandara; Kathrin Klein; Neil A Miller; Teri E Klein; Rachel F Tyndale; Michelle Whirl-Carrillo; Andrea Gaedigk Journal: Clin Pharmacol Ther Date: 2021-03-11 Impact factor: 6.903
Authors: A Joseph Bloom; Maribel Martinez; Li-Shiun Chen; Laura J Bierut; Sharon E Murphy; Alison Goate Journal: PLoS One Date: 2013-11-15 Impact factor: 3.240